Advertisement
Advertisement
U.S. Markets open in 7 hrs 48 mins
Advertisement
Advertisement
Advertisement
Advertisement

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.43+4.02 (+7.82%)
At close: 04:00PM EDT
55.76 +0.33 (+0.60%)
After hours: 04:26PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close51.41
Open50.27
Bid0.00 x 1000
Ask0.00 x 1300
Day's Range49.00 - 55.56
52 Week Range34.90 - 98.67
Volume554,599
Avg. Volume449,766
Market Cap2.931B
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-3.80
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.35
  • Zacks

    Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

    Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “This is an exciting time at Arvinas as we remain on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year, have a clear development pathway fo

  • GlobeNewswire

    Arvinas Appoints John Northcott as Chief Commercial Officer

    NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO). “John is an excellent addition to the Arvinas leadership team, and I am confident that his experience and impressive product development and commercialization track record will play an imp

Advertisement
Advertisement